K. Moores

发表

Octimibate, a potent non‐prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor

T. Rink, J. Macdermot, T. Hallam, 1991, British journal of pharmacology.

The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function

T. Rink, J. Maguire, T. Hallam, 1990, British journal of pharmacology.

CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound.

I. Forbes, P. Groot, R. Ife, 2000, Bioorganic & Medicinal Chemistry Letters.

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor.

D. Tew, H. Boyd, D. Dhanak, 1999, The Biochemical journal.

Cloning, in Vitro Expression, and Functional Characterization of a Novel Human CC Chemokine of the Monocyte Chemotactic Protein (MCP) Family (MCP-4) That Binds and Signals through the CC Chemokine Receptor 2B*

H. Sarau, J. Foley, N. Elshourbagy, 1997, The Journal of Biological Chemistry.

PPARγ Is Not a Critical Mediator of Primary Monocyte Differentiation or Foam Cell Formation

S. J. Newman, J. Clapham, Stephen A. Smith, 2002 .

Involvement of calcium in modulation of neutrophil function by phorbol esters that activate protein kinase C isotypes and related enzymes.

J. Merritt, K. Moores, P. Sharma, 1993, The Biochemical journal.

Fractalkine Is Expressed by Smooth Muscle Cells in Response to IFN-γ and TNF-α and Is Modulated by Metalloproteinase Activity1

P. Groot, A. Ludwig, K. Moores, 2002, The Journal of Immunology.

Sema7A is a Potent Monocyte Stimulator

A. Fosberry, G. Pettman, D. Michalovich, 2002, Scandinavian journal of immunology.

The discovery of SB-435495. A potent, orally active inhibitor of lipoprotein-associated phospholipase A(2) for evaluation in man.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2002, Bioorganic & medicinal chemistry letters.

Identification of a truncated form of the CC chemokine CK beta-8 demonstrating greatly enhanced biological activity.

J. White, C. Imburgia, J. Fornwald, 1998, Journal of immunology.

The role of fractalkine in the recruitment of monocytes to the endothelium.

P. Green, K. Moores, T. Berkhout, 2000, European journal of pharmacology.

Cloning and functional characterization of a novel human CC chemokine that binds to the CCR3 receptor and activates human eosinophils

H. Sarau, J. Foley, N. Elshourbagy, 1997, Journal of leukocyte biology.

Identification of a sulfonamide series of CCR2 antagonists.

Carl A. Brooks, V. Piercy, R. Ife, 2010, Bioorganic & medicinal chemistry letters.

Targeted replacement of rodent CCR2 with the human orthologue CCR2B: A mouse model for in vivo analysis of human target‐selective small molecule MCP‐1 receptor antagonists

I. Forbes, H. Prosser, P. Groot, 2002 .

In vivo activity of an azole series of CCR2 antagonists.

Carl A. Brooks, V. Piercy, P. Gough, 2012, Bioorganic & medicinal chemistry letters.

Use of fluo-3 to measure cytosolic Ca2+ in platelets and neutrophils. Loading cells with the dye, calibration of traces, measurements in the presence of plasma, and buffering of cytosolic Ca2+.

S. Mccarthy, J. Merritt, K. Moores, 1990, The Biochemical journal.

Pharmacological Characterization of a Novel ENaCα siRNA (GSK2225745) With Potential for the Treatment of Cystic Fibrosis

R. Mayer, Paul A. Wilson, V. Jadhav, 2013, Molecular therapy. Nucleic acids.

Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor.

C. Southan, D. Tew, S. Rice, 1998, The Biochemical journal.

CCR2: characterization of the antagonist binding site from a combined receptor modeling/mutagenesis approach.

I. Forbes, F. Blaney, A. Bridges, 2003, Journal of medicinal chemistry.

N-1 substituted pyrimidin-4-ones: novel, orally active inhibitors of lipoprotein-associated phospholipase A2.

D. Tew, H. Boyd, I. Stansfield, 2000, Bioorganic & medicinal chemistry letters.

SK&F 96365, a novel inhibitor of receptor-mediated calcium entry.

T. Rink, S. Mccarthy, C. Benham, 1990, The Biochemical journal.

Human neutrophils have a novel purinergic P2-type receptor linked to calcium mobilization.

J. Merritt, K. Moores, 1991, Cellular signalling.

In silico and in vitro evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization

Emma L. Koppe, T. Gant, N. Gooderham, 2015, Nucleic acids research.

Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs

T. Gant, J. Ridings, N. Gooderham, 2017, Molecular therapy. Nucleic acids.

Fractalkine Cleavage from Neuronal Membranes Represents an Acute Event in the Inflammatory Response to Excitotoxic Brain Damage

K. Moores, P. Strijbos, B. Stewart, 2000, The Journal of Neuroscience.

Selective binding of the truncated form of the chemokine CKbeta8 (25-99) to CC chemokine receptor 1(CCR1).

J. White, P. Groot, K. Moores, 2000, Biochemical pharmacology.

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

Hung‐Yuan Cheng, Stephen A. Smith, I. Stansfield, 2003, Bioorganic & medicinal chemistry letters.

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins.

C. Southan, D. Tew, S. Rice, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Anti-atherosclerotic effect of SB-244323, a lipoprotein associated phospholipase A2 inhibitor, in WHHL rabbits

D. Tew, H. Boyd, K. Suckling, 2000 .

Fractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activity.

P. Groot, A. Ludwig, K. Moores, 2002, Journal of immunology.

Design and synthesis of a series of glycerol-derived receptor mediated calcium entry (RMCE) blockers

T. Rink, K. Cassidy, R. Dolle, 1990 .